<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="66335">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02242305</url>
  </required_header>
  <id_info>
    <org_study_id>202.838</org_study_id>
    <nct_id>NCT02242305</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of Hyoscine Butylbromide Tablets for the Treatment of Occasional or Recurrent Episodes of Gastric or Intestinal Spasm-like Pain or Discomfort</brief_title>
  <official_title>A Randomized, Double-blind, Double-dummy, Active-controlled, Parallel-group, Multi-center Trial, in Contrast With Hyoscine Butylbromide Capsule 10mg, to Evaluate the Efficacy and Safety of Hyoscine Butylbromide Tablets 10 mg (20mg, 3 Times Daily, Orally) Over a Period of 3 Days for the Treatment of Occasional or Recurrent Episodes of Self-reported Gastric or Intestinal Spasm-like Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      In contrast with Hyoscine Butylbromide Capsule 10mg, Study is to evaluate the efficacy and
      safety of Hyoscine Butylbromide tablets 10 mg (20mg, 3 times daily, orally) over a period of
      3 days for the treatment of occasional or recurrent episodes of self-reported gastric or
      intestinal spasm-like pain or discomfort
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double-Blind</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of the mean pain intensity score measured on a verbal analogue scale (VAS)</measure>
    <time_frame>up to 3 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of the pain frequency assessed on 4-stage verbal rating scale (VRS)</measure>
    <time_frame>up to 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of efficacy by patient on 4-point scale</measure>
    <time_frame>after 3 days of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of tolerability by investigator on a 4-point scale</measure>
    <time_frame>at Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of tolerability by subject on a 4-point scale</measure>
    <time_frame>at Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with abnormal changes in laboratory parameters</measure>
    <time_frame>up to 3 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">302</enrollment>
  <condition>Abdominal Pain</condition>
  <arm_group>
    <arm_group_label>Hyoscine Butylbromide - Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyoscine Butylbromide - Capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyoscine Butylbromide - Tablet</intervention_name>
    <arm_group_label>Hyoscine Butylbromide - Tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyoscine Butylbromide - Capsule</intervention_name>
    <arm_group_label>Hyoscine Butylbromide - Capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Hyoscine Butylbromide - Tablet</arm_group_label>
    <arm_group_label>Hyoscine Butylbromide - Capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written Informed Consent given by the patient

          2. Male and female patients aging from 18 to 70

          3. Subjects with occasional or recurrent episodes of gastric or intestinal spasm-like
             pain, or discomfort, such as occur e.g. in irritable bowel syndrome, which has been
             present for at least 3 months

          4. The pain intensity score upon screening is at least 4 cm in VAS score

        Exclusion Criteria:

          1. Patients with the following concomitant disease were not eligible for enrolment

               -  Painful gastric or intestinal spasm of organic origin such as Crohn's disease,
                  ulcerative colitis, lactose intolerance, gastritis, ulcer. Exception:
                  diverticulitis and mild gastritis if dominant symptom was cramp pain, but
                  ineligible if heartburn or reflux were dominant symptoms

               -  Pain related with malignancy

               -  Patients with other severe pain states of organic origin

               -  Mechanical stenosis of the gastrointestinal tract, megacolon

               -  Urinary retention associated with mechanical stenosis of urinary tract

               -  Narrow-angled glaucoma

               -  Tachyarrhythmia

               -  Myasthenia gravis

               -  Meulengracht-Gilbert syndrome

               -  Known depression or known mental illness, anxiety disturbance

          2. Frequent vomiting that might have prevented adequate absorption of the active
             ingredient after the film-coated tablet was taken

          3. Patients taking the following concomitant medication are not eligible for enrolment

               -  Analgesics

               -  Spasmolytics

               -  Anticholinergics

               -  Affecting gastrointestinal motility, such as propantheline metoclopramide,
                  cisapride, loperamide, diphenoxylate, opioid analgesics, antacids and other
                  ulcer treatment

               -  Regular administration of laxatives

               -  Narcotics

               -  Antidepressant treatment or treatment with psychoactive drugs

          4. Pregnancy and/or lactation or planned pregnancy

          5. Known hypersensitivity to N-butylscopolammonium bromide

          6. Alcohol or drug abuse

          7. Simultaneous participating in another clinical trial, or discontinuing from another
             clinical trial before randomization (administration of study medication); moreover,
             in the case of screening failure or premature discontinuing from the trial, repeated
             enrolment is forbidden

          8. Unwilling to or unable to complete the entire trial procedure according to the
             protocol

          9. In investigator's opinion, the patient was not proper for the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>September 2014</verification_date>
  <lastchanged_date>September 16, 2014</lastchanged_date>
  <firstreceived_date>September 16, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Abdominal Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Scopolamine Hydrobromide</mesh_term>
    <mesh_term>Butylscopolammonium Bromide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
